Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As usual this share drops before a big rise. What do you think todays increase is for?
Jayne,
Yes orphan drug status can only help and in view of the trial results you'd hope that there's a good chance of approval for RDEB patients - time will tell but looking at the price movement today it seems others may think so too.
Jimbob,
Have only just noticed your post to me a couple of weeks ago - sorry for not replying. I'm good thanks and hope you and yours are keeping well too. I'm not in ORPH but know a couple who are and who are very positive about it. Did you buy in the end?
Novelion took a large number of Amryt Shares ( 14,040,250 ) for the sale of Aegerion. These were to be distributed to the Novelion shareholders as part of ongoing Liquidation.
There could be sales from that source.
This share is a keeper for me.
Hi Bermuda, very much appreciate your thoughtful reply - thank you for that and the knowledgeable advice (I'm familiar with some of your posts over on Scancell). Yes, the suffering in DEB is unimagineable and that's gleaned from close observation over many years.
The trial data looks very promising to me, but though I've done my research and tried to be pragmatic, I'm not so clear about the processes for approval post-trial, so appreciate your objectivity. I hoped orphan status might make approval more likely.
I know we shouldn't be emotional about our investments, however I've been careful to only invest what I can afford to lose here if push came to shove - the access to a treatment that works for sufferers - even partially - definitely means a whole lot more. Best regards, Jayne
Jayne,
Given the lack of any approved treatments for EB, the bar must be set fairly low for approval. We can only hope that Filsuvez will become the first approval for EB and will make a real difference to patients' lives.
Very sorry to hear that you had a very close family member with D/EB - you will know better than any here the suffering involved and what a truly dreadful disease it is. Fingers crossed for a swift approval followed quickly by reimbursement approvals from healthcare providers/insurers so that patients actually have access to the treatment.
Bronxville, interesting observation. Sudocreme was used for daily treatment for D/EB for many years (I had a very close family member w/DEB who we lost a couple of years ago). I imagine the amount of Filsuvez required daily when approved will be similar. The regularly affected wound areas for DEB sufferers will likely need to be literally slathered in the stuff daily before being dressed. Put it this way, a very large tub of Sudocreme wouldn't last longer than a month.
Filsuvez's efficacy in trials looks like it will be a big help for DEB sufferers in particular, which I'm profoundly grateful for (even if sadly too late for my much-loved one). That it makes great business sense with my investor head on is the icing on the cake.
Must be real positive on Filsuvez and Stafford knows his ointments.
Where are the multi millionaires in the USA and all their friends and why aren't they getting involved.
One concern I had here however on the volumes, was on the day before 11th March, there was almost £180k worth of shares sold in largish tranches. (a large multiple of daily average) then we have these purchased today. Any thoughts guys?
I remain bullish re AMYT
It is an Option Exercise.
It was an OPTION exercise as per RNS dated 12th March.
Hopefully less selling pressure
Approval of Filsuvez means Amryt will get 'priority review voucher' valued at $100 mil.
I think its the structure of the debt of Amryt that causing issues.
That said ADR's are trading at $15 today so something is out of sync.
As time goes on do approvals for Filsuvez mean the amryt share price would actually drop as payments are triggered to to the cvr holders? Perhaps not by the full amount but some strong downside risk, meaning hodl the cvr's but sell the shares?
Well that's a surprise..(annoying)
I'll be taking some off the table here when they file with the FDA later this month.
Yep they feel like they have a good network in place now for partnerships within the 'Orphan Space' (that have approval) that they can grow to $100 million in sales and are actively looking.
Any mention on the call of target assets or M&A, Bronx?
After the institutional raise, I also think the market wants to see what Joe does with the proceeds before it commits to re-rating us to where we should be....
I think ?? people are scared away by the financing structure.
No doubt it should be higher..
Good call really.
The last 1 I had to take a double expresso to stay awake.
Joe Wiley's mundane presentation style is mind numbing.
There is some volume today on the Nasdaq but its an indictment of management that they have not created more interest in this equity..
Case of doing your own research but you will probably have 4 companies for the price of 1 in relation to Open Orphan in the next 6 mths.
I know I got in very early ( and its harder to pull the trigger now) but I'm not selling until I get a share in the spinoff's.The first coming probably before the end of March.
Reply from Paps,Thanks
..a solid gainer but definitely not a multi bagger..(and we have our CVR's)..............
Hi Bronxville. There was a 1 for 6 consolidation when AMYT RTO'd into Novelion's Aegerion subsidiary. So the 24p that AMYT floated at in 2016 after the 1 for 8 consolidation following the FAST RTO is equivalent to 144p following the 1 for 6 consolidation on relisting after the Aegerion deal in 2019. So the current AMYT share price of 213p is effectively a 48% increase on the 24p 2016 issue price.